Ubc cre ert2 ubc cre

Tek-Cre⁺ (stock no. 008863), Prx1-Cre⁺ (stock no. 005584) and Ubc-Cre-ERT2⁺ (Ubc-Cre⁺) (stock no. 007001) mice were procured from Jackson Laboratory. Cxcl12^f/f mice (loxP sites flanking exon 2) were crossed with Tek-Cre⁺, Prx1-Cre⁺ and Ubc-Cre⁺ mice to generate Cxcl12^f/f-Tek-Cre⁺ (Cxcl12^−/− EC) (Agarwal et al., 2019 (link)), Cxcl12^f/f-Prx1-Cre⁺ (Cxcl12^−/− MPC) (Agarwal et al., 2019 (link)), and Cxcl12^f/f-Ubc-Cre⁺ (Cxcl12^−/−) mice. Loss of CXCL12 expression in endothelial cells (Cxcl12^−/− EC) and mesenchymal progenitor cells (Cxcl12^−/− MPC) from these mice was previously confirmed by real time PCR (Agarwal et al., 2019 (link)). Global deletion of Cxcl12 in Cxcl12^f/f-Ubc-Cre⁺ mice was achieved by administration of 50 mg/kg of tamoxifen (Sigma-Aldrich; Cat no. T5648) in corn oil through intraperitoneal injections for five consecutive days. All mice were maintained in an AAALAC-accredited animal facility, and all procedures were carried out in accordance with federal guidelines and protocols approved by the Institutional Animal Care and Use Committee at the University of Alabama, Birmingham.